Skip to main content
KISSEI PHARMACEUTICAL CO.,LTD. logo

KISSEI PHARMACEUTICAL CO.,LTD. — Investor Relations & Filings

Ticker · 4547 ISIN · JP3240600001 T Manufacturing
Open in API
Filings indexed 79 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country JP Japan
Listing T 4547

About KISSEI PHARMACEUTICAL CO.,LTD.

https://www.kissei.co.jp/e_contents/

Kissei Pharmaceutical Co., Ltd. is a research-driven company engaged in the discovery, development, manufacturing, and sale of pharmaceutical products. The company concentrates its research and development investments in key therapeutic areas, including urology, renal diseases and dialysis, and rare or intractable diseases. Its broader product portfolio also addresses conditions in metabolic and endocrinological, obstetrics and gynecological, and ophthalmic fields. Committed to creating innovative medicines, Kissei aims to contribute to global health by addressing unmet medical needs. The company also operates in the health foods sector.

Recent filings

Filing Released Lang Actions
タブネオスの安全性確保のための注意喚起について
Regulatory Filings Classification · 75% confidence The document is a corporate press release notifying a safety alert (‘ブルーレター’) and label revision for a pharmaceutical product by the company, with no financial statements, no shareholder votes, no management changes, nor proxy or dividend information. It is a regulatory compliance announcement regarding drug safety. This falls under the general regulatory announcements/fallback category.
2026-05-21 Japanese
2026年3月期 決算説明会資料
Investor Presentation Classification · 90% confidence The document is a 2026年3月期 決算説明会 (‘financial results presentation’) slide deck by the company president, containing detailed performance summaries, segment results, pipeline updates, and future outlook. It clearly serves as an investor presentation rather than a concise earnings release or statutory annual report. This matches the definition of an Investor Presentation (Code: IP).
2026-05-12 Japanese
自己株式の取得及び自己株式の消却に関するお知らせ
Transaction in Own Shares Classification · 90% confidence The document is a formal announcement by Kisai Pharmaceutical Co., Ltd. regarding the Board resolution to acquire (buy back) up to 1,300,000 shares of its own common stock and subsequently cancel those treasury shares under Companies Act provisions. This clearly describes a share repurchase and cancellation (transaction in own shares). It is not a financing update, governance notice, or dividend; it matches the definition of “Transaction in Own Shares.”
2026-05-11 Japanese
2026年3月期 決算補足資料
Investor Presentation Classification · 87% confidence The document is titled “決算補足資料” (supplementary materials for financial results) for the full‐year (通期) fiscal 2026 and contains detailed slide‐style tables (P&L, balance sheet, cash flow, dividends, segment/product performance) along with narrative commentary and forecasts. This is not the statutory Annual Report (10‐K) nor a mere brief earnings release, but rather a comprehensive slide presentation aimed at investors. It matches our definition of an Investor Presentation (IP).
2026-05-11 Japanese
2026年3月期 決算短信〔日本基準〕（連結）
Earnings Release Classification · 95% confidence The document is titled “決算短信〔日本基準〕(連結)” and is a Japanese ‘kessan tanshin’ – a preliminary earnings announcement containing consolidated financial highlights for the fiscal year ended March 2026, key ratios, dividend information, and forecasts for the next fiscal year. It explicitly notes that it is not subject to audit (“決算短信は公認会計士又は監査法人の監査の対象外です”) and provides summary tables of results and projections, consistent with an Earnings Release rather than a full Annual Report or audited financial statements. Therefore, it should be classified as an Earnings Release. FY 2026
2026-05-11 Japanese
急性骨髄性白血病治療薬オルタシデニブのオリエントユーロファーマ社（台湾）への技術導出契約締結のお知らせ
Regulatory Filings
2026-05-01 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.